Compounds 1, 2 and 4 dose-dependently down-regulated TNFα-induced NF-κB activity in human chronic myeloid leukemia cells with IC50s of 38.5 ± 1.2 μM, 65.7 ± 2.0 μM and 82.7 ± 11.3 μM, respectively. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.